Hiv breaking news 2018

Here are some significant HIV-related news stories from 2018:

January 2018

• The World Health Organization (WHO) recommends that all people living with HIV, regardless of their CD4 count, should start antiretroviral therapy (ART) as soon as possible after diagnosis. This change in guidelines aims to improve treatment outcomes and reduce the risk of transmission. (Source: WHO)

February 2018

• A study published in The Lancet finds that a daily dose of tenofovir, a common HIV medication, can reduce the risk of HIV transmission from mother to child by 70%. The study was conducted in South Africa and involved over 2,000 pregnant women. (Source: The Lancet)

March 2018

• The US Food and Drug Administration (FDA) approves a new HIV treatment, Descovy, which is a combination of emtricitabine and tenofovir alafenamide. Descovy is designed to be used as a treatment for HIV-1 infection in adults and children who are 12 years of age and older. (Source: FDA)

April 2018

• A study published in the Journal of the American Medical Association (JAMA) finds that a pre-exposure prophylaxis (PrEP) regimen consisting of daily tenofovir disoproxil fumarate and emtricitabine can reduce the risk of HIV infection in men who have sex with men (MSM) by 86%. The study was conducted in the United States and involved over 4,500 participants. (Source: JAMA)

May 2018

• The Centers for Disease Control and Prevention (CDC) reports that the number of new HIV diagnoses in the United States has declined by 18% since 2010. However, the CDC also notes that HIV remains a significant public health threat, particularly among certain populations such as MSM and black/African American individuals. (Source: CDC)

June 2018

• A study published in The New England Journal of Medicine finds that a single injection of cabotegravir, a long-acting antiretroviral medication, can prevent HIV infection in MSM for up to 12 weeks. The study was conducted in South Africa and involved over 4,500 participants. (Source: NEJM)

July 2018

• The FDA approves a new HIV treatment, Genvoya, which is a combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide. Genvoya is designed to be used as a treatment for HIV-1 infection in adults and children who are 12 years of age and older. (Source: FDA)

August 2018

• A study published in the Journal of Infectious Diseases finds that a combination of antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP) can reduce the risk of HIV transmission from mother to child by 90%. The study was conducted in South Africa and involved over 1,000 pregnant women. (Source: Journal of Infectious Diseases)

September 2018

• The WHO launches a new initiative to eliminate HIV transmission from mother to child by 2025. The initiative aims to improve access to antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP) for pregnant women and their partners. (Source: WHO)

October 2018

• A study published in The Lancet finds that a daily dose of dolutegravir, a common HIV medication, can reduce the risk of HIV transmission from mother to child by 74%. The study was conducted in Malawi and involved over 1,000 pregnant women. (Source: The Lancet)

November 2018

• The FDA approves a new HIV treatment, Biktarvy, which is a combination of bictegravir, emtricitabine, and tenofovir alafenamide. Biktarvy is designed to be used as a treatment for HIV-1 infection in adults and children who are 12 years of age and older. (Source: FDA)

December 2018

• The WHO reports that the number of people living with HIV has increased by 18% since 2010, with an estimated 38 million people living with HIV worldwide. The WHO also notes that progress has been made in reducing HIV-related deaths and new infections, but more work is needed to achieve the goal of ending the HIV epidemic by 2030. (Source: WHO)

These are just a few of the significant HIV-related news stories from 2018.